MARKET

PRTK

PRTK

Paratek Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.51
-0.63
-7.74%
Opening 14:29 06/18 EDT
OPEN
8.00
PREV CLOSE
8.14
HIGH
8.29
LOW
7.41
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
11.24
52 WEEK LOW
4.110
MARKET CAP
352.43M
P/E (TTM)
-3.9017
1D
5D
1M
3M
1Y
5Y
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront.
Benzinga · 1d ago
Opthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losers
Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%, Fusion Pharmaceuticals (FUS...
Seekingalpha · 2d ago
Paratek Pharma Shares Drop 16% After Opening Sites for Nuzyra Trials
marketwatch.com · 2d ago
Paratek Launches Mid-Stage NTM Program With Nuzyra, Second Procurement Under BARDA Pact Expected In 2H 2022
Benzinga · 2d ago
Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Paratek Pharmaceuticals (PRTK) announces the initiation of clinical trial sites for its Phase 2b study exploring the potential utility of Nuzyra (omadacycline) as a treatment for Nontuberculous Mycobacterial ((NTM)) Pulmonary
Seekingalpha · 2d ago
BRIEF-Paratek Pharmaceuticals Announces Initiation Of Phase 2B Study In Nontuberculous Mycobacterial Pulmonary Disease
reuters.com · 2d ago
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA(R) (omadacycline)
-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment
GlobeNewswire · 2d ago
Paratek Initiates Phase 2b Study of Nuzyra in Nontuberculous Mycobacterial Pulmonary Disease; Lowers Revenue Expectation
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTK. Analyze the recent business situations of Paratek Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTK stock price target is 18.40 with a high estimate of 34.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 161
Institutional Holdings: 33.09M
% Owned: 70.51%
Shares Outstanding: 46.93M
TypeInstitutionsShares
Increased
25
1.44M
New
8
219.25K
Decreased
40
965.83K
Sold Out
10
393.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.10%
Pharmaceuticals & Medical Research
-1.10%
Key Executives
Chairman/Executive Director
Michael Bigham
President
Adam Woodrow
Chief Executive Officer/Director
Evan Loh
General Counsel/Secretary
William Haskel
Other
Randall Brenner
Independent Director
Minnie Baylor-Henry
Director
Rolf Hoffman
Independent Director
Thomas Dietz
Independent Director
Timothy Franson
Independent Director
Rolf Hoffmann
Independent Director
Kristine Peterson
Independent Director
Robert Radie
Independent Director
Jeffrey Stein
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 1.33
06/04/2014
About PRTK
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTK stock methods without spending real money on the virtual paper trading platform.